HC Wainwright Issues Positive Outlook for Kamada Earnings

Kamada Ltd. (NASDAQ:KMDA - Free Report) - Analysts at HC Wainwright boosted their Q2 2025 earnings per share (EPS) estimates for Kamada in a note issued to investors on Friday, May 16th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings per share of $0.11 for the quarter, up from their prior forecast of $0.06. HC Wainwright currently has a "Buy" rating and a $11.00 target price on the stock. The consensus estimate for Kamada's current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Kamada's FY2026 earnings at $0.42 EPS.

Kamada (NASDAQ:KMDA - Get Free Report) last posted its earnings results on Wednesday, May 14th. The biotechnology company reported $0.07 earnings per share for the quarter, meeting analysts' consensus estimates of $0.07. Kamada had a net margin of 9.92% and a return on equity of 6.30%. The firm had revenue of $44.02 million during the quarter, compared to analyst estimates of $154.06 million.

Other research analysts have also issued research reports about the company. Sidoti upgraded Kamada to a "hold" rating in a research report on Thursday, May 8th. Wall Street Zen upgraded Kamada from a "buy" rating to a "strong-buy" rating in a report on Wednesday. Finally, Benchmark reaffirmed a "buy" rating and set a $15.00 price objective on shares of Kamada in a research note on Thursday, May 15th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Kamada has an average rating of "Buy" and an average price target of $14.67.

Kamada Stock Performance

Shares of NASDAQ:KMDA traded down $0.11 on Monday, reaching $6.63. The company's stock had a trading volume of 64,599 shares, compared to its average volume of 90,300. Kamada has a 52-week low of $4.74 and a 52-week high of $9.16. The company has a market cap of $381.09 million, a P/E ratio of 23.68, a PEG ratio of 0.97 and a beta of 0.94. The company has a 50-day simple moving average of $6.57 and a 200 day simple moving average of $6.62.

Kamada Announces Dividend

The firm also recently announced a -- dividend, which was paid on Monday, April 7th. Shareholders of record on Monday, March 17th were given a dividend of $0.20 per share. The ex-dividend date was Monday, March 17th.

Institutional Trading of Kamada

A number of large investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its holdings in shares of Kamada by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock valued at $178,000 after purchasing an additional 1,549 shares during the period. Aristides Capital LLC grew its holdings in Kamada by 12.1% during the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock worth $387,000 after acquiring an additional 6,850 shares in the last quarter. NewEdge Advisors LLC grew its holdings in Kamada by 54.2% during the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock worth $143,000 after acquiring an additional 8,260 shares in the last quarter. JPMorgan Chase & Co. bought a new position in Kamada during the 4th quarter worth about $67,000. Finally, Trexquant Investment LP bought a new position in Kamada during the 1st quarter worth about $82,000. 20.38% of the stock is owned by hedge funds and other institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.